MX388461B - Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva. - Google Patents

Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.

Info

Publication number
MX388461B
MX388461B MX2018012739A MX2018012739A MX388461B MX 388461 B MX388461 B MX 388461B MX 2018012739 A MX2018012739 A MX 2018012739A MX 2018012739 A MX2018012739 A MX 2018012739A MX 388461 B MX388461 B MX 388461B
Authority
MX
Mexico
Prior art keywords
cognitive function
leucine
acetyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2018012739A
Other languages
English (en)
Spanish (es)
Other versions
MX2018012739A (es
Inventor
Mallory Factor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MX2018012739A publication Critical patent/MX2018012739A/es
Publication of MX388461B publication Critical patent/MX388461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2018012739A 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva. MX388461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (2)

Publication Number Publication Date
MX2018012739A MX2018012739A (es) 2019-06-17
MX388461B true MX388461B (es) 2025-03-20

Family

ID=58633040

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012739A MX388461B (es) 2016-04-19 2017-04-19 Acetil-leucina o una sal farmacéuticamente aceptable de la misma para mejorar la movilidad y función cognitiva.
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014844A MX2021014844A (es) 2016-04-19 2018-10-18 Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.

Country Status (26)

Country Link
US (4) US10905670B2 (enExample)
EP (2) EP3445351B1 (enExample)
JP (3) JP7387264B2 (enExample)
KR (4) KR102632670B1 (enExample)
CN (2) CN109069463B (enExample)
AU (2) AU2017252507B2 (enExample)
BR (1) BR112018071547A2 (enExample)
CA (2) CA3309723A1 (enExample)
DK (1) DK3445351T3 (enExample)
ES (1) ES2994242T3 (enExample)
FI (1) FI3445351T3 (enExample)
HR (1) HRP20241552T1 (enExample)
HU (1) HUE069219T2 (enExample)
IL (3) IL293266B2 (enExample)
LT (1) LT3445351T (enExample)
MD (1) MD3445351T2 (enExample)
MX (2) MX388461B (enExample)
PL (1) PL3445351T3 (enExample)
PT (1) PT3445351T (enExample)
RS (1) RS66142B1 (enExample)
RU (1) RU2745912C2 (enExample)
SG (2) SG10202106190RA (enExample)
SI (1) SI3445351T1 (enExample)
SM (1) SMT202400459T1 (enExample)
WO (1) WO2017182802A1 (enExample)
ZA (1) ZA201806849B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3445351T (pt) 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
TN2019000033A1 (fr) 2016-08-11 2020-07-15 Intrabio Ltd Agents thérapeutiques pour maladies neurodégénératives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
CN120157593A (zh) 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN119097618A (zh) * 2019-03-02 2024-12-10 内在生物技术有限公司 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物
MD3989962T2 (ro) * 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
WO2025019570A1 (en) 2023-07-18 2025-01-23 Sytheon Ltd. Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity
WO2025166100A1 (en) 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
AU2007352854A1 (en) * 2007-05-08 2008-11-13 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
WO2011025518A1 (en) * 2009-08-27 2011-03-03 Albert Einstein College Of Medicine Of Yeshiva University Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
PT3445351T (pt) * 2016-04-19 2024-11-14 Intrabio Ltd Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade
EP3697406A1 (en) * 2017-10-18 2020-08-26 IntraBio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders

Also Published As

Publication number Publication date
PL3445351T3 (pl) 2025-01-07
RS66142B1 (sr) 2024-12-31
CA3021155A1 (en) 2017-10-26
DK3445351T3 (da) 2024-11-04
KR20180134398A (ko) 2018-12-18
US20190083438A1 (en) 2019-03-21
EP3445351A1 (en) 2019-02-27
JP2022024058A (ja) 2022-02-08
KR102632670B1 (ko) 2024-02-01
SI3445351T1 (sl) 2025-04-30
JP2024123087A (ja) 2024-09-10
SG11201809031XA (en) 2018-11-29
IL262379A (en) 2018-11-29
AU2022256077A1 (en) 2022-11-17
JP2019513814A (ja) 2019-05-30
FI3445351T3 (fi) 2024-11-18
EP4501406A2 (en) 2025-02-05
RU2021107001A (ru) 2021-04-12
ZA201806849B (en) 2019-07-31
JP7506046B2 (ja) 2024-06-25
SMT202400459T1 (it) 2025-01-14
KR102791288B1 (ko) 2025-04-03
CN118593463A (zh) 2024-09-06
NZ747307A (en) 2025-10-31
HRP20241552T1 (hr) 2025-01-17
IL310508A (en) 2024-03-01
LT3445351T (lt) 2024-11-25
US20230346732A1 (en) 2023-11-02
US11998518B2 (en) 2024-06-04
RU2018140131A3 (enExample) 2020-05-14
IL293266B1 (en) 2024-03-01
US20250332133A1 (en) 2025-10-30
US10905670B2 (en) 2021-02-02
EP3445351B1 (en) 2024-10-16
US12329733B2 (en) 2025-06-17
KR20220038814A (ko) 2022-03-29
AU2017252507B2 (en) 2022-07-21
MD3445351T2 (ro) 2024-12-31
CN109069463B (zh) 2024-07-23
KR102413754B1 (ko) 2022-06-27
IL262379B (en) 2022-07-01
WO2017182802A1 (en) 2017-10-26
MX2021014844A (es) 2022-01-18
SG10202106190RA (en) 2021-07-29
MX2018012739A (es) 2019-06-17
EP4501406A3 (en) 2025-03-26
BR112018071547A2 (pt) 2019-03-06
HUE069219T2 (hu) 2025-02-28
JP7387264B2 (ja) 2023-11-28
CN109069463A (zh) 2018-12-21
KR20220093386A (ko) 2022-07-05
RU2745912C2 (ru) 2021-04-02
ES2994242T3 (en) 2025-02-05
AU2017252507A1 (en) 2018-11-08
IL293266A (en) 2022-07-01
PT3445351T (pt) 2024-11-14
IL293266B2 (en) 2024-07-01
KR20240018683A (ko) 2024-02-13
CA3309723A1 (en) 2026-06-21
US20210106548A1 (en) 2021-04-15
RU2018140131A (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2018012739A (es) Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva.
IL272089B1 (en) Compounds, compositions and methods
CL2017003033A1 (es) Dispositivo de monitorización para la aplicación de un fármaco con una pluma de fármaco, con registro, comunicación y alarmas.
TWD172100S (zh) 化粧瓶
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
TWD178500S (zh) 護膚器
MX378273B (es) Compuestos activos hacia bromodominios.
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
PT3454676T (pt) Utilização de probióticos para melhorar a absorção de proteínas
TWD166031S (zh) 口含物
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
AR110404A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l
TWD180565S (zh) 塗抹器
TWD175621S (zh) 髮梳
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.
TWD175370S (zh) 按摩器
LT3015109T (lt) Biologinis barjeras su simetikonu, skirtas panaudoti nosies-ryklės-vamzdelių infekcijų gydymui
TWD195659S (zh) Washstand
TWD170668S (zh) 記事板